reference/20269235

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20269235

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	253
issn	1757-4684 1757-4676
issueIdentifier	2
pageRange	239-253
publicationName	EMBO Molecular Medicine
startingPage	239
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_3b0d9beddbffd53d2722c2299d3b6dd7 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a7471f307da5ca65876c13b71b94b743 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f2b0ac8e38674f08b0ca4c8db8f64e98 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_fdb95f94008cff51464e99b04994a610
bibliographicCitation	Trochet D, Prudhon B, Beuvin M, Peccate C, Lorain S, Julien L, Benkhelifa-Ziyyat S, Rabai A, Mamchaoui K, Ferry A, Laporte J, Guicheney P, Vassilopoulos S, Bitoun M. Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy. EMBO Mol Med. 2018 Feb;10(2):239–53. PMID: 29246969; PMCID: PMC5801507.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4188-7918 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-8256-5862 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_57d808748389ce11b56078b05bb5be27 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6050-4556 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9216-6117 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3be3918e82ff7ac88ea9c9a3945f0190 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e417d3cdf3bb0848c5b147abf493bc0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5f174bc5bca0247147ff6cda3524dc36 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_95aff7fa3c289a30912dc3ee6b7cdedb http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5266-9994 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_92c2a26f82cd7ba1281e6bf8baec8e23 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_455dd252899f7ecbcbbbf0af1f97fec1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a29dac0316ca378bc8b8a9b305d1e4e5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38eb4d07434774f8b8a5dd045b99638a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f1450348926ccb00d38c96d19d9ae410 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b73d6a78ed941c19f4fc1e33168251f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7663-2050
date	2017-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/29246969 https://pubmed.ncbi.nlm.nih.gov/PMC5801507 https://doi.org/10.15252/emmm.201707988
isPartOf	https://portal.issn.org/resource/ISSN/1757-4676 https://portal.issn.org/resource/ISSN/1757-4684 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/36713
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Allele‐specific silencing therapy for Dynamin 2‐related dominant centronuclear myopathy
discusses	http://id.nlm.nih.gov/mesh/M0406100 http://id.nlm.nih.gov/mesh/M0171124
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D015316 http://id.nlm.nih.gov/mesh/D020914Q000188 http://id.nlm.nih.gov/mesh/D020914Q000503 http://id.nlm.nih.gov/mesh/D034741Q000627 http://id.nlm.nih.gov/mesh/D020914Q000201 http://id.nlm.nih.gov/mesh/D034285Q000235
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000483 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000818 http://id.nlm.nih.gov/mesh/D009154 http://id.nlm.nih.gov/mesh/D051379 http://id.nlm.nih.gov/mesh/D002478
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cb0fec75731fd2fc8ffb60d181574f2d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10658 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8655 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10737

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID13430

Total number of triples: 60.